Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
27
BIS Quote, Financials, Valuation and Earnings
Last price:
$8.91
Seasonality move
:
-7.3%
Day range:
$8.67 - $8.93
52-week range:
$8.31 - $25.87
Dividend yield:
4.82%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
8K
Avg. volume:
15.4K
1-year change:
-53.7%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, ProShares UltraShort Nasdaq Biotechnology has -- downside to fair value with a price target of -- per share.
BIS vs. S&P 500
-
Over the past 5 trading days, ProShares UltraShort Nasdaq Biotechnology has underperformed the S&P 500 by -8.3% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ProShares UltraShort Nasdaq Biotechnology does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ProShares UltraShort Nasdaq Biotechnology has grown year-over-year revenues for 0 quarters straight. In the most recent quarter ProShares UltraShort Nasdaq Biotechnology reported revenues of --.
Earnings Growth
-
ProShares UltraShort Nasdaq Biotechnology has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ProShares UltraShort Nasdaq Biotechnology reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2024-04-03 | 2025-04-03 | 2025-04-03 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2022-04-03 | 2023-04-03 | 2024-04-03 | 2025-04-03 | ||
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | -- | |
| Total Assets | -- | -- | -- | -- | -- | |
| Current Liabilities | -- | -- | -- | -- | -- | |
| Total Liabilities | -- | -- | -- | -- | -- | |
| Total Equity | -- | -- | -- | -- | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2024-04-03 | 2025-04-03 | 2025-04-03 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
BIS
Sector
Market Cap
--
--
Price % of 52-Week High
33.92%
--
Dividend Yield
4.82%
--
Shareholder Yield
--
--
1-Year Price Total Return
-53.7%
--
Beta (5-Year)
-1.419
--
Dividend yield:
4.82%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$9.26
200-day SMA
Sell
Level
$11.76
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$9.24
Relative Strength Index (RSI14)
Sell
Level
44.50
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-85.1111
50-day SMA
Sell
Level
$8.90
MACD (12, 26)
Buy
Level
0.05
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
--
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Stock Forecast FAQ
In the current month, BIS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BIS average analyst price target in the past 3 months is --.
-
Where Will ProShares UltraShort Nasdaq Biotechnology Stock Be In 1 Year?
According to analysts, the consensus estimate is that ProShares UltraShort Nasdaq Biotechnology share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About ProShares UltraShort Nasdaq Biotechnology?
Analysts are divided on their view about ProShares UltraShort Nasdaq Biotechnology share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ProShares UltraShort Nasdaq Biotechnology is a Sell and believe this share price will rise from its current level to --.
-
What Is ProShares UltraShort Nasdaq Biotechnology's Price Target?
The price target for ProShares UltraShort Nasdaq Biotechnology over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BIS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ProShares UltraShort Nasdaq Biotechnology is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BIS?
You can purchase shares of ProShares UltraShort Nasdaq Biotechnology via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ProShares UltraShort Nasdaq Biotechnology shares.
-
What Is The ProShares UltraShort Nasdaq Biotechnology Share Price Today?
ProShares UltraShort Nasdaq Biotechnology was last trading at $8.91 per share. This represents the most recent stock quote for ProShares UltraShort Nasdaq Biotechnology. Yesterday, ProShares UltraShort Nasdaq Biotechnology closed at $8.77 per share.
-
How To Buy ProShares UltraShort Nasdaq Biotechnology Stock Online?
In order to purchase ProShares UltraShort Nasdaq Biotechnology stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BIS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BIS
Sector
P/E ratio
--
--
PEG ratio
--
--
P/B ratio
--
--
Price / LTM sales
--
--
Growth Metrics
BIS
Sector
Revenue growth
--
--
Earnings growth
--
--
Revenue (5-year growth)
--
--
Earnings forecast
--
--
Profitability
BIS
Sector
Profitability FY 2026
--
--
Return on invested capital
--
--
Return on assets
--
--
Return on equity
--
--
Earnings Date
Last Earnings Date
Apr
3
Next Earnings Date
Apr
3
Estimated Next Earnings Date
Jul
3
Balance Sheet
BIS
Sector
Total cash
--
--
Short term investments
--
--
Total assets
--
--
Long term debt
--
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
72
RGC alert for Apr 2
Regencell Bioscience Holdings Ltd. [RGC] is down 8.66% over the past day.
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Sell
27
RH alert for Apr 2
RH [RH] is up 0.51% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
